NEW YORK (GenomeWeb) – Precipio said on Friday that it expects a 200 percent year-over-year increase in fourth quarter revenues, driven primarily by its pathology diagnostic services and pharma projects run in its lab.
For the three-month period ended Dec. 31, 2017 Precipio posted preliminary revenues of $945,000 compared with $316,000 generated in the year-ago quarter.